Búsqueda | Portal de Búsqueda de la BVS España

1.

Noonan syndrome-causing SHP2 mutants impair ERK-dependent chondrocyte differentiation during endochondral bone growth.

Tajan, Mylène; Pernin-Grandjean, Julie; Beton, Nicolas; Gennero, Isabelle; Capilla, Florence; Neel, Benjamin G; Araki, Toshiyuki; Valet, Philippe; Tauber, Maithé; Salles, Jean-Pierre; Yart, Armelle; Edouard, Thomas.

Hum Mol Genet; 27(13): 2276-2289, 2018 07 01.

Artículo en Inglés | MEDLINE | ID: mdl-29659837

2.

LEOPARD syndrome-associated SHP2 mutation confers leanness and protection from diet-induced obesity.

Tajan, Mylène; Batut, Aurélie; Cadoudal, Thomas; Deleruyelle, Simon; Le Gonidec, Sophie; Saint Laurent, Céline; Vomscheid, Maëlle; Wanecq, Estelle; Tréguer, Karine; De Rocca Serra-Nédélec, Audrey; Vinel, Claire; Marques, Marie-Adeline; Pozzo, Joffrey; Kunduzova, Oksana; Salles, Jean-Pierre; Tauber, Maithé; Raynal, Patrick; Cavé, Hélène; Edouard, Thomas; Valet, Philippe; Yart, Armelle.

Proc Natl Acad Sci U S A; 111(42): E4494-503, 2014 Oct 21.

Artículo en Inglés | MEDLINE | ID: mdl-25288766

3.

Noonan syndrome-causing SHP2 mutants inhibit insulin-like growth factor 1 release via growth hormone-induced ERK hyperactivation, which contributes to short stature.

De Rocca Serra-Nédélec, Audrey; Edouard, Thomas; Tréguer, Karine; Tajan, Mylène; Araki, Toshiyuki; Dance, Marie; Mus, Marianne; Montagner, Alexandra; Tauber, Maïté; Salles, Jean-Pierre; Valet, Philippe; Neel, Benjamin G; Raynal, Patrick; Yart, Armelle.

Proc Natl Acad Sci U S A; 109(11): 4257-62, 2012 Mar 13.

Artículo en Inglés | MEDLINE | ID: mdl-22371576

4.

The Tyrosine Phosphatase SHP2: A New Target for Insulin Resistance?

Saint-Laurent, Céline; Mazeyrie, Laurène; Tajan, Mylène; Paccoud, Romain; Castan-Laurell, Isabelle; Valet, Philippe; Edouard, Thomas; Pradère, Jean-Philippe; Dray, Cédric; Yart, Armelle.

Biomedicines; 10(9)2022 Aug 31.

Artículo en Inglés | MEDLINE | ID: mdl-36140242

5.

PHGDH is required for germinal center formation and is a therapeutic target in MYC-driven lymphoma.

D'Avola, Annalisa; Legrave, Nathalie; Tajan, Mylène; Chakravarty, Probir; Shearer, Ryan L; King, Hamish W; Kluckova, Katarina; Cheung, Eric C; Clear, Andrew J; Gunawan, Arief S; Zhang, Lingling; James, Louisa K; MacRae, James I; Gribben, John G; Calado, Dinis P; Vousden, Karen H; Riches, John C.

J Clin Invest; 132(9)2022 05 02.

Artículo en Inglés | MEDLINE | ID: mdl-35316216

6.

The impact of physiological metabolite levels on serine uptake, synthesis and utilization in cancer cells.

Hennequart, Marc; Labuschagne, Christiaan F; Tajan, Mylène; Pilley, Steven E; Cheung, Eric C; Legrave, Nathalie M; Driscoll, Paul C; Vousden, Karen H.

Nat Commun; 12(1): 6176, 2021 10 26.

Artículo en Inglés | MEDLINE | ID: mdl-34702840

7.

Serine synthesis pathway inhibition cooperates with dietary serine and glycine limitation for cancer therapy.

Tajan, Mylène; Hennequart, Marc; Cheung, Eric C; Zani, Fabio; Hock, Andreas K; Legrave, Nathalie; Maddocks, Oliver D K; Ridgway, Rachel A; Athineos, Dimitris; Suárez-Bonnet, Alejandro; Ludwig, Robert L; Novellasdemunt, Laura; Angelis, Nikolaos; Li, Vivian S W; Vlachogiannis, Georgios; Valeri, Nicola; Mainolfi, Nello; Suri, Vipin; Friedman, Adam; Manfredi, Mark; Blyth, Karen; Sansom, Owen J; Vousden, Karen H.

Nat Commun; 12(1): 366, 2021 01 14.

Artículo en Inglés | MEDLINE | ID: mdl-33446657

8.

SHP2 drives inflammation-triggered insulin resistance by reshaping tissue macrophage populations.

Paccoud, Romain; Saint-Laurent, Céline; Piccolo, Enzo; Tajan, Mylène; Dortignac, Alizée; Pereira, Ophélie; Le Gonidec, Sophie; Baba, Inès; Gélineau, Adélaïde; Askia, Haoussa; Branchereau, Maxime; Charpentier, Julie; Personnaz, Jean; Branka, Sophie; Auriau, Johanna; Deleruyelle, Simon; Canouil, Mickaël; Beton, Nicolas; Salles, Jean-Pierre; Tauber, Maithé; Weill, Jacques; Froguel, Philippe; Neel, Benjamin G; Araki, Toshiyuki; Heymes, Christophe; Burcelin, Rémy; Castan, Isabelle; Valet, Philippe; Dray, Cédric; Gautier, Emmanuel L; Edouard, Thomas; Pradère, Jean-Philippe; Yart, Armelle.

Sci Transl Med; 13(591)2021 04 28.

Artículo en Inglés | MEDLINE | ID: mdl-33910978

9.

Dietary Approaches to Cancer Therapy.

Tajan, Mylène; Vousden, Karen H.

Cancer Cell; 37(6): 767-785, 2020 06 08.

Artículo en Inglés | MEDLINE | ID: mdl-32413275

10.

PHGDH is required for germinal center formation and is a therapeutic target in MYC-driven lymphoma.

D'Avola, Annalisa; Legrave, Nathalie; Tajan, Mylène; Chakravarty, Probir; Shearer, Ryan L; King, Hamish W; Kluckova, Katarina; Cheung, Eric C; Clear, Andrew J; Gunawan, Arief S; Zhang, Lingling; James, Louisa K; MacRae, James I; Gribben, John G; Calado, Dinis P; Vousden, Karen H; Riches, John C.

J Clin Invest; 134(4)2024 Feb 15.

Artículo en Inglés | MEDLINE | ID: mdl-38357928

11.

The RASopathy Family: Consequences of Germline Activation of the RAS/MAPK Pathway.

Tajan, Mylène; Paccoud, Romain; Branka, Sophie; Edouard, Thomas; Yart, Armelle.

Endocr Rev; 39(5): 676-700, 2018 10 01.

Artículo en Inglés | MEDLINE | ID: mdl-29924299

12.

A Role for p53 in the Adaptation to Glutamine Starvation through the Expression of SLC1A3.

Tajan, Mylène; Hock, Andreas K; Blagih, Julianna; Robertson, Neil A; Labuschagne, Christiaan F; Kruiswijk, Flore; Humpton, Timothy J; Adams, Peter D; Vousden, Karen H.

Cell Metab; 28(5): 721-736.e6, 2018 11 06.

Artículo en Inglés | MEDLINE | ID: mdl-30122553

13.

The Quid Pro Quo of the Tumor/Stromal Interaction.

Tajan, Mylène; Vousden, Karen H.

Cell Metab; 24(5): 645-646, 2016 11 08.

Artículo en Inglés | MEDLINE | ID: mdl-27829131

14.

SHP2 sails from physiology to pathology.

Tajan, Mylène; de Rocca Serra, Audrey; Valet, Philippe; Edouard, Thomas; Yart, Armelle.

Eur J Med Genet; 58(10): 509-25, 2015 Oct.

Artículo en Inglés | MEDLINE | ID: mdl-26341048

Portal de Búsqueda de la BVS España

Información y Conocimiento para la Salud

Configurar filtros

Su selección (0)

Formato de exportación:

Exportar:

Noonan syndrome-causing SHP2 mutants impair ERK-dependent chondrocyte differentiation during endochondral bone growth.

LEOPARD syndrome-associated SHP2 mutation confers leanness and protection from diet-induced obesity.

Noonan syndrome-causing SHP2 mutants inhibit insulin-like growth factor 1 release via growth hormone-induced ERK hyperactivation, which contributes to short stature.

The Tyrosine Phosphatase SHP2: A New Target for Insulin Resistance?

PHGDH is required for germinal center formation and is a therapeutic target in MYC-driven lymphoma.

The impact of physiological metabolite levels on serine uptake, synthesis and utilization in cancer cells.

Serine synthesis pathway inhibition cooperates with dietary serine and glycine limitation for cancer therapy.

SHP2 drives inflammation-triggered insulin resistance by reshaping tissue macrophage populations.

Dietary Approaches to Cancer Therapy.

PHGDH is required for germinal center formation and is a therapeutic target in MYC-driven lymphoma.

The RASopathy Family: Consequences of Germline Activation of the RAS/MAPK Pathway.

A Role for p53 in the Adaptation to Glutamine Starvation through the Expression of SLC1A3.

The Quid Pro Quo of the Tumor/Stromal Interaction.

SHP2 sails from physiology to pathology.